Announced Sat, 23 May · 13:40 IST

Audited Financial Results (Standalone and Consolidated) for the year ended 31st March 2026

Pat NegativeResults View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+11.9%1-day move
₹65.25
prior close
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+11.9+14.4+14.5+14.2+0.4+5.0+4.2-7.9
Up moveDown movePending
AI summary

Relic Technologies Ltd reported audited annual results for FY2026 with an unmodified (clean) audit opinion from D. Kothary & Co. Standalone total assets doubled from Rs 1,002.85 lakhs to Rs 2,046.59 lakhs year-over-year, while cash and cash equivalents surged from Rs 0.95 lakhs to Rs 764.04 lakhs. Trade receivables grew significantly from Rs 202.97 lakhs to Rs 1,233.25 lakhs, though this large receivable position warrants monitoring. On a consolidated basis, the company includes two subsidiaries (Relic Pharma Limited and Truhealthy Wellness Private Limited), which collectively reported a net loss of Rs 748.69 lakhs for the year, indicating headwinds from subsidiary operations. Pre-tax profit on standalone basis stood at Rs 1,070.30 lakhs. The auditors confirmed no material uncertainties regarding the company's ability to continue as a going concern.

Likely market impact

The clean audit opinion and strong standalone asset growth are positive signals, though investors should note the substantial consolidated losses from subsidiaries and the high trade receivables balance which could indicate aggressive revenue recognition or customer payment delays.